# A Study to Evaluate Safety and Efficacy of SAGE-547 in Participants With Moderate Postpartum Depression (547-PPD-202C)

> **NCT02942017** · PHASE3 · COMPLETED · sponsor: **Supernus Pharmaceuticals, Inc.** · enrollment: 108 (actual)

## Conditions studied

- Postpartum Depression

## Interventions

- **DRUG:** Placebo
- **DRUG:** SAGE-547 90 μg/kg/h

## Key facts

- **NCT ID:** NCT02942017
- **Lead sponsor:** Supernus Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-07
- **Primary completion:** 2017-09-17
- **Final completion:** 2017-10-11
- **Target enrollment:** 108 (ACTUAL)
- **Last updated:** 2025-09-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02942017

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02942017, "A Study to Evaluate Safety and Efficacy of SAGE-547 in Participants With Moderate Postpartum Depression (547-PPD-202C)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02942017. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*